Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: Effectively treated with Pirfenidone
<p>The coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has led to a pandemic situation. According to the WHO classification, COVID-19 patients could be classified with severity as uncomplicated illness, mild pneumonia, severe pneumonia,...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | Zhan Xi (Συγγραφέας), Zhao Zhigang (Συγγραφέας), Li Ting (Συγγραφέας) |
---|---|
Μορφή: | Βιβλίο |
Έκδοση: |
Archives of Pulmonology and Respiratory Care - Peertechz Publications,
2020-06-23.
|
Θέματα: | |
Διαθέσιμο Online: | Connect to this object online. |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Role of pirfenidone in the management of pulmonary fibrosis
από: Meyer KC, κ.ά.
Έκδοση: (2017) -
Pirfenidone treatment of idiopathic pulmonary fibrosis
από: Ye Gan, κ.ά.
Έκδοση: (2011) -
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
από: Maria Chianese, κ.ά.
Έκδοση: (2024) -
Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
από: Wencheng Yu, κ.ά.
Έκδοση: (2017) -
Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
από: José M. Serra López-Matencio, κ.ά.
Έκδοση: (2021)